BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng M, Wang P. Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease. 3 Biotech 2021;11:179. [PMID: 33927970 DOI: 10.1007/s13205-021-02738-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Eraky SM, Ramadan NM, Abo El-Magd NF. Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway. Int J Biol Macromol 2023;227:1119-31. [PMID: 36462588 DOI: 10.1016/j.ijbiomac.2022.11.291] [Reference Citation Analysis]
2 Bazzari FH, Bazzari AH. BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future? Molecules 2022;27. [PMID: 36557955 DOI: 10.3390/molecules27248823] [Reference Citation Analysis]
3 Flores A, Moyano P, Sola E, García JM, García J, Anadon MJ, Frejo MT, Naval MV, Fernadez MDLC, Pino JD. Single and repeated bisphenol A treatment induces ROS, Aβ and hyperphosphorylated-tau accumulation, and insulin pathways disruption, through HDAC2 and PTP1B overexpression, leading to SN56 cholinergic apoptotic cell death. Food and Chemical Toxicology 2022;170:113500. [DOI: 10.1016/j.fct.2022.113500] [Reference Citation Analysis]
4 Singh DD, Shati AA, Alfaifi MY, Elbehairi SEI, Han I, Choi EH, Yadav DK. Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. Cells 2022;11. [PMID: 36497027 DOI: 10.3390/cells11233767] [Reference Citation Analysis]
5 Du H, Meng X, Yao Y, Xu J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. Front Endocrinol (Lausanne) 2022;13:1033479. [PMID: 36465634 DOI: 10.3389/fendo.2022.1033479] [Reference Citation Analysis]
6 Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem 2022. [DOI: 10.1007/s11010-022-04587-x] [Reference Citation Analysis]
7 Kang J, Oteiza PI, Milenkovic D. (-)-Epicatechin exerts positive effects on anxiety in high fat diet-induced obese mice through multi-genomic modifications in the hippocampus. Food Funct 2022. [PMID: 36168829 DOI: 10.1039/d2fo01897g] [Reference Citation Analysis]
8 Ganne A, Balasubramaniam M, Griffin WST, Shmookler Reis RJ, Ayyadevara S. Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease. Pharmaceutics 2022;14:1354. [DOI: 10.3390/pharmaceutics14071354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Athauda D, Evans J, Wernick A, Virdi G, Choi ML, Lawton M, Vijiaratnam N, Girges C, Ben-Shlomo Y, Ismail K, Morris H, Grosset D, Foltynie T, Gandhi S. The Impact of Type 2 Diabetes in Parkinson's Disease. Mov Disord 2022. [PMID: 35699244 DOI: 10.1002/mds.29122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Fehsel K, Christl J. Comorbidity of osteoporosis and Alzheimer's disease: Is `AKT `-ing on cellular glucose uptake the missing link? Ageing Res Rev 2022;76:101592. [PMID: 35192961 DOI: 10.1016/j.arr.2022.101592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Carranza-Naval MJ, Del Marco A, Hierro-Bujalance C, Alves-Martinez P, Infante-Garcia C, Vargas-Soria M, Herrera M, Barba-Cordoba B, Atienza-Navarro I, Lubian-Lopez S, Garcia-Alloza M. Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes. Front Aging Neurosci 2021;13:741923. [PMID: 34975451 DOI: 10.3389/fnagi.2021.741923] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
12 Athauda D, Evans J, Wernick A, Virdi G, Liane-choi M, Lawton M, Vijiaratnam N, Girges C, Ben-shlomo Y, Ismail K, Morris H, Grosset D, Foltynie T, Gandhi S. The impact of Type 2 diabetes in Parkinson’s disease.. [DOI: 10.1101/2021.10.21.21265308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]